On March 17, 2026 Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, reported that a poster with preclinical data on the Company’s oral KAT6A selective degrader (PRT13722) has been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place from April 17-22.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing additional preclinical data from our potent and selective first-in-class KAT6A degrader development candidate, PRT13722. We believe that our selective KAT6A degrader, with the potential for improved efficacy and tolerability in combination with other standard of care agents, has the potential to be a promising new therapy for patients with ER+ breast cancer. We expect to file an IND in the middle of this year and enter clinical trials in the second half of 2026," stated Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude.

Details on the poster presentation are as follows:

Poster Details:
Title: First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile.
Session Category: Experimental and Molecular Therapeutics
Session Title: Proximity-Induced Drug Discovery 2
Session Start: 4/21/2026 2:00 PM
Session End: 4/21/2026 5:00 PM
Location: Poster Section 15
Poster Board Number: 20
Poster Number: 5793

Highly selective KAT6A oral degrader program
KAT6 is an emerging and recently validated target in the treatment of ER+ breast cancer. Prelude discovered and is developing first-in-class, highly potent, highly selective and orally bioavailable KAT6A selective degraders. The Company has selected a development candidate and remains on track to file an IND in mid-2026 with phase 1 study initiation planned in the 2nd half of 2026. Prelude believes that selectively degrading KAT6A has the potential for improved efficacy, tolerability and combinability with other agents relative to non-selective inhibitors of KAT6A/B and KAT7.

The Company presented initial preclinical data supporting this hypothesis at the AACR (Free AACR Whitepaper) Annual Meeting 2025. The presentation can be found at Publications – Prelude Therapeutics.

Additionally, on April 18, 2026, Prelude’s Director of Biology and Translational Research, Norman Fultang, Ph.D. will be providing a lecture during an educational session entitled: ED08 – Chemistry to the Clinic Part 1 of 4: Next-Level Conjugates: Transforming Targeted Therapies. The title of the presentation is: "Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes with Targeted Protein Degrader-Antibody Conjugates (DACs)."

(Press release, Prelude Therapeutics, MAR 17, 2026, View Source [SID1234663667])

On March 17, 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported that it will participate in a fireside chat at the 38th Annual ROTH Conference being held March 22-24, 2026 in Dana Point, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the fireside chat presentation are as follows:

Date and Time: Tuesday, March 24, 2026 at 12:00-12:25 PM PT
Location: BROWN – HEALTHCARE – VIRTUAL (SUITE 1051)
Presenters: Walter Klemp, Founder, President, Chairman & CEO; Jon Foster, EVP & CFO
Registration Link: Here

Investors interested in arranging one-on-one meetings should contact their ROTH representative. For more information, please visit the conference website.

(Press release, Moleculin, MAR 17, 2026, View Source [SID1234663619])

On March 17, 2026 Pixelgen Technologies reported a research collaboration with Andreas Lundqvist’s Group at the Department of Oncology-Pathology, Karolinska Institutet, to discover novel biomarkers for cancer immunotherapy response using Pixelgen’s Proximity Network Assay (PNA). The project will explore the spatial distribution and abundance of more than 150 cell surface proteins in patients with non-small lung cancer who undergo immunotherapy with immune checkpoint inhibitors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Pixelgen’s Proximity Network Assay has the potential to bring new insights into the organization and interactions of cell surface proteins, which could aid in the discovery of new biomarkers for immune checkpoint inhibition response and consequently inform treatment regimens for patients," Prof. Andreas Lundqvist said. "While other tools provide protein abundance analysis, Pixelgen’s PNA brings a new dimension of understanding to the spatial organization and interactions of cell surface proteins that may prove useful for patient stratification."

The collaboration combines the tumor immunology and biology expertise from Prof. Lundqvist’s group and Pixelgen’s technology and experience in cell surface protein interactomics. The team aims to submit results from the project to a scientific journal for peer-reviewed publication, and the research will lay the groundwork for future collaborations.

"We’re very excited to embark on this collaboration with Prof. Lundqvist’s group, which has made significant contributions to tumor immunology, particularly in the areas of immune escape and advancing cell-based therapeutic approaches," said Pixelgen Chief Business Development Officer Erik Pettersson. "Our hope is that this research will contribute to the understanding of the role single-cell protein interactions have in disease, identify biomarkers for immunotherapy response, and ultimately lead to the development of improved immunotherapies for cancer patients."

Pixelgen’s PNA delivers nanoscale spatial analysis of immune cell proteins at scale, as part of the company’s Pixelgen Proxiome Kit. The technology is used by researchers looking for new avenues for drug and biomarker discovery and diagnostics in immunology, immuno-oncology, hematology, and cell therapy.

(Press release, Karolinska Institutet, MAR 17, 2026, https://www.prnewswire.com/news-releases/pixelgen-technologies-and-andreas-lundqvists-research-group-at-karolinska-institutet-collaborate-to-identify-novel-biomarkers-for-cancer-immunotherapy-302715490.html [SID1234663636])

On March 17, 2026 Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, reported that preclinical data from its IL-15 and IL-18 programs will be presented at the 2026 AACR (Free AACR Whitepaper) Annual Meeting held April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IL-15 Programs: FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein and has demonstrated best-in-class (BIC) profile as monotherapy in heavily pre-treated patients with late stage solid tumors, of which 3 patients (~10%) remain on treatment and progression-free currently at 9, 11 and 20 months respectively. Poster 7932 further elucidated mechanism of action underlying FL115 BIC profile, with Cryo-EM analysis of FL115/FcRn/β2M complex. In vivo, RNA-Seq and single-cell transcriptomics revealed FL115 reshaped the tumor microenvironment by enhancing NK and T cells infiltration without not triggering activation of neutrophils and macrophage. Poster 6459 showed significant potential of FL115 subcutaneous formulation. Compared to IV injection, subcutaneous injection of FL115 resulted in drastic lowering of Cmax (up to 26.7×) with bioavailability at ~60% as well as good linearity in PK file. FL115 at approximately 9 mg per injection site in rabbits showed no significant gross skin irritation.

IL-18 Programs: using structural modeling with our AI-driven Intelligent Biomolecular Discovery Platform, we developed a series of engineered IL-18 variants (IL-18v) that fully escape IL-18BP neutralization while providing tunable IL-18R1 affinity, enabling customizable cytokine potency, as described in Poster 7779. Based on one such IL-18v, we developed FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody.
Poster 1777 showed FL116 achieved potent anti-tumor activities and rechallenge-confirmed immune memory while maintaining systemic immune homeostasis in multiple tumor models, and re-ignited intratumoral cytotoxic immunity while reshaping the TME toward a highly inflamed, effector-dominant state.

"Forlong’s pipeline strategy is to modulate the immune system with precision via stimulation of specific immune cell subpopulation through engineered cytokines, providing new options for patients," said Dong Wei, Ph.D., Chief Executive Officer of Forlong Biotechnology, "IL-15 and IL-18 have long been believed to be attractive cytokines for cancer immunotherapy, and we appreciate the opportunity to present initial data of FL115 and FL116 programs to leading immuno-oncology experts in this prestigious forum."

Poster Details:

Title: A tunable interleukin-18 (IL-18) platform engineered for complete escape from the decoy receptor IL-18 binding protein (IL-18BP)
Poster Number: 7779
Date & Time: 4/22/2026

Title: FL116, a PD-1/IL-18 bispecific antibody, enables cis-activation of PD-1⁺ T cells and reshapes the suppressive tumor microenvironment (TME)
Poster Number: 1777
Date & Time: 4/20/2026

Title: FL115, a novel IL-15 superagonist rationally designed to minimize safety risks for cancer immunotherapy
Poster Number: 7932
Date & Time: 4/22/2026

Title: Development of FL115, a novel IL-15 superagonist, as subcutaneous injection for cancer immunotherapy
Poster Number: 6459
Date & Time: 4/21/2026

About FL-115

FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein, aiming to enhance anti-tumor immunity via IL-15-mediated signaling on NK and CD8+ T cells while minimizing complexity from Fc. FL115 has demonstrated significant anti-tumor activities as a monotherapy or as part of combination therapy in vivo, and can be manufactured by a robust and efficient process with excellent product stability. Clinically, FL115 has demonstrated favorable safety profile and preliminary clinical responses as a monotherapy, and has the best-in-class potential to synergize with current and emerging T cell-targeting immunotherapies through combination therapy to significantly improve the treatment outcome for patients. It is currently being investigated in combination with Bacillus Calmette-Guérin (BCG) in a Phase 2 clinical trial to evaluate safety and preliminary efficacy in patients with nonmuscle invasive bladder cancer (NMIBC) and in combination with an anti-PD1 monoclonal antibody in a Phase 1b/2 clinical trial to evaluate safety and preliminary efficacy in patients with advanced solid tumors.

(Press release, Forlong Biotechnology, MAR 17, 2026, View Source [SID1234663652])

On March 17, 2026 Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported it will present two preclinical posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 17-22 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details
Title: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha
Poster/Abstract: 2950
Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs
Date/Time: April 20, 2026, from 2:00-5:00pm PT / 5:00pm-8:00pm ET

Title: Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures
Poster/Abstract: 2949
Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs
Date/Time: April 20, 2026, from 2:00pm-5:00pm PT / 5:00pm-8:00pm ET

Additional information can be found on the AACR (Free AACR Whitepaper) Annual Meeting website.

(Press release, Olema Oncology, MAR 17, 2026, View Source [SID1234663668])